A Phase 1 interventional study of Azenosertib and Carboplatin in Solid Tumor, Epithelial Ovarian Cancer and Fallopian Tube Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. Recruiting at 35 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Carcinoma, Ovarian Epithelial with a site in France — 10 open to participants now, 14 under way, 5 of them phase 3. Carcinoma, Ovarian Epithelial · France.
Among the 46 studies in Carcinoma, Ovarian Epithelial with a site in France, this one is the 25th largest by planned enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 in phase 1, reaches primary completion later than 7 of the 13 other live ones, and was the 34th registered.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
Browse Carcinoma, Ovarian Epithelial studies →10 of the 46 studies in Carcinoma, Ovarian Epithelial with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Argentina and 26 more countries
Ages 18+ · Women only
AstraZeneca · Sites in France, United States, Australia and 21 more countries
Ages 18+ · Women only
Daiichi Sankyo · Sites in France, United States, Australia and 23 more countries
Ages 18+ · Women only
TORL Biotherapeutics, LLC · Sites in France, United States, Australia and 9 more countries
Ages 18+ · Women only
Guardant Health, Inc. · Sites in France, United States, Germany and 2 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 17
First in 1996; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 172 is above the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Median enrollment 245 across the 40 interventional studies, 500 across the 5 observational. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 46 have an industry lead sponsor. The 10 most frequent:
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc has 1 study filed under Carcinoma, Ovarian Epithelial — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Ovarian Epithelial with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03976999Institut du Cancer de Montpellier - Val d'AurelleDevelopment of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | 2027-07 |
| NCT05238922Incyte CorporationStudy of INCB123667 in Subjects With Advanced Solid Tumors | 2027-07-27 |
| NCT06690775TORL Biotherapeutics, LLCCATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | 2027-10 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies in Carcinoma, Ovarian Epithelial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
This is a Phase 1b open-label, multicenter study evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (also known as ZN-c3) in combination with chemotherapy or bevacizumab. This study consists of 2 parts:
Part 1 (completed and no longer recruiting): Azenosertib in combination with chemotherapy Azenosertib was assessed in combination with chemotherapy in subjects with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer.
Part 2: Azenosertib in combination with bevacizumab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Part 1:
For Part 2 Dose Escalation:
Prior therapy:
Response to prior platinum therapy:
In the 2L setting:
Complete Response, Partial Response, or Stable Disease to 2L platinum-based chemotherapy.
For Part 2 Dose Expansion:
EXCLUSION CRITERIA:
Additional protocol-defined exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azenosertib in combination with carboplatin
Drug: Azenosertib · Drug: Carboplatin
Azenosertib in combination with pegylated liposomal doxorubicin (PLD)
Drug: Azenosertib · Drug: Pegylated liposomal doxorubicin
Azenosertib in combination with paclitaxel
Drug: Azenosertib · Drug: Paclitaxel
Azenosertib in combination with gemcitabine
Drug: Azenosertib · Drug: Gemcitabine
Azenosertib in combination with bevacizumab
Drug: Azenosertib · Biological: Bevacizumab
Investigational drug
Also known as: ZN-c3
Carboplatin is an approved drug
Pegylated liposomal doxorubicin (PLD) is an approved drug
Paclitaxel is an approved drug
Gemcitabine is an approved drug
Bevacizumab is an approved drug
Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine
Incidence and severity of adverse events (AEs)
Time frame: Through study completion, an average of 1 year
Part 1: To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine
Incidence and severity of dose-limiting toxicities (DLTs)
Time frame: Through Cycle 1 (cycle is 28 days for PLD or paclitaxel, and 21 days for carboplatin, or gemcitabine)
Part 2: To estimate the safety/tolerability of azenosertib in combination with bevacizumab
Incidence and severity of adverse events (AEs) Incidence of dose interruptions, reductions, and discontinuations due to treatment-related AEs
Time frame: Through study completion, an average of 1 year
Part 2: To identify the recommended dose for Part 2 Dose Expansion
Time frame: Through Cycle 1 (21 days)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Jun 2028, 92 months after the start.
Of 55 phase 1 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 81. This study's planned 92 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Ovarian Epithelial →
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc